Patient and Healthcare Professional Satisfaction, Acceptability, and Preference Experiences With Mirikizumab Administration for Ulcerative Colitis: An International Survey
Both patients and HCPs were satisfied with and accepted mirikizumab IV induction followed by monthly maintenance SC injections. UC improvement outweighed any administration dissatisfaction.
Authors
- Theresa Hunter (ORCID: https://orcid.org/0000-0001-8412-9175)
- Joe Milata
- David B. Clemow (ORCID: https://orcid.org/0000-0002-5328-8285)
- Yuka Ito (ORCID: https://orcid.org/0000-0002-7020-6990)
- Karla Alaka
- Danielle N. Rodriguez (ORCID: https://orcid.org/0000-0002-1135-6999)
- Christine Radawski (ORCID: https://orcid.org/0000-0001-8487-6680)
- Nicholas Martinez
- Adam Schaum
- Obi Ezennia
- Tibor Szalóki
- Katherine A. Kirk
Institutions
- Ithaka Harbors (US)
- Eli Lilly (United States) (US)
- American Gastroenterological Association (US)
- National Hospital Organization Mito Medical Center (JP)
Publication Details
- Journal
- Crohn s & Colitis 360
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1093/crocol/otae054
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company